Shareholders might have noticed that Nektar Therapeutics (NASDAQ:NKTR) filed its quarterly result this time last week. The early response was not positive, with shares down 3.5% to US$36.44 in the past week. Revenues of US$9.4m came in a modest 9.8% below forecasts. Statutory losses were a relative bright spot though, with a per-share loss of US$1.63 coming in a substantial 21% smaller than what the analysts had expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Nektar Therapeutics after the latest results.
Following last week's earnings report, Nektar Therapeutics' 15 analysts are forecasting 2027 revenues to be US$51.2m, approximately in line with the last 12 months. Per-share losses are expected to explode, reaching US$9.77 per share. Before this earnings announcement, the analysts had been modelling revenues of US$53.4m and losses of US$10.50 per share in 2027. So there seems to have been a moderate uplift in analyst sentiment with the latest consensus release, given the upgrade to loss per share forecasts for next year.
View our latest analysis for Nektar Therapeutics
The analysts have cut their price target 8.6% to US$132per share, suggesting that the declining revenue was a more crucial indicator than the forecast reduction in losses. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values Nektar Therapeutics at US$192 per share, while the most bearish prices it at US$40.00. With such a wide range in price targets, analysts are almost certainly betting on widely divergent outcomes in the underlying business. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. One thing that stands out from these estimates is that shrinking revenues are expected to moderate over the period ending 2027 compared to the historical decline of 11% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 21% per year. So while a broad number of companies are forecast to grow, unfortunately Nektar Therapeutics is expected to see its revenue affected worse than other companies in the industry.
The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. On the negative side, they also downgraded their revenue estimates, and forecasts imply they will perform worse than the wider industry. Even so, earnings per share are more important to the intrinsic value of the business. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.
With that in mind, we wouldn't be too quick to come to a conclusion on Nektar Therapeutics. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Nektar Therapeutics analysts - going out to 2028, and you can see them free on our platform here.
However, before you get too enthused, we've discovered 3 warning signs for Nektar Therapeutics (2 are a bit concerning!) that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.